US80105N1054 - ADR

**SNY** gets a fundamental rating of **7** out of 10. The analysis compared the fundamentals against 205 industry peers in the **Pharmaceuticals** industry. **SNY** scores excellent points on both the profitability and health parts. This is a solid base for a good stock. A decent growth rate in combination with a cheap valuation! Better keep an eye on **SNY**. **SNY** also has an excellent dividend rating. With these ratings, **SNY** could be worth investigating further for value and dividend and quality investing!.

In the past year **SNY** had a positive cash flow from operations.

Each year in the past 5 years **SNY** has been profitable.

Each year in the past 5 years **SNY** had a positive operating cash flow.

The **Return On Assets** of **SNY** (**10.12%**) is better than **93.17%** of its industry peers.

The **Return On Equity** of **SNY** (**17.47%**) is better than **91.22%** of its industry peers.

With an excellent **Return On Invested Capital** value of **15.53%**, **SNY** belongs to the best of the industry, outperforming **92.20%** of the companies in the same industry.

The last **Return On Invested Capital** (**15.53%**) for **SNY** is above the 3 year average (**6.95%**), which is a sign of increasing profitability.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 10.12% | ||

ROE | 17.47% | ||

ROIC | 15.53% |

ROA(3y)7.51%

ROA(5y)5.77%

ROE(3y)13.25%

ROE(5y)10.34%

ROIC(3y)6.95%

ROIC(5y)6.41%

In the last couple of years the **Profit Margin** of **SNY** has declined.

The **Operating Margin** of **SNY** (**27.75%**) is better than **94.15%** of its industry peers.

The **Gross Margin** of **SNY** (**70.31%**) is better than **78.54%** of its industry peers.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 27.75% | ||

PM (TTM) | 18.09% | ||

GM | 70.31% |

OM growth 3Y7.11%

OM growth 5Y2.17%

PM growth 3Y36.08%

PM growth 5Y-4.51%

GM growth 3Y0.81%

GM growth 5Y0.55%

Compared to 1 year ago, **SNY** has about the same amount of shares outstanding.

Compared to 5 years ago, **SNY** has about the same amount of shares outstanding.

The debt/assets ratio for **SNY** has been reduced compared to a year ago.

An Altman-Z score of **3.07** indicates that **SNY** is not in any danger for bankruptcy at the moment.

Looking at the **Altman-Z score**, with a value of **3.07**, **SNY** is in the better half of the industry, outperforming **77.07%** of the companies in the same industry.

With an excellent **Debt to FCF ratio** value of **2.59**, **SNY** belongs to the best of the industry, outperforming **90.73%** of the companies in the same industry.

With a **Debt to Equity ratio** value of **0.22**, **SNY** perfoms like the industry average, outperforming **43.41%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.22 | ||

Debt/FCF | 2.59 | ||

Altman-Z | 3.07 |

ROIC/WACC2.23

WACC6.96%

With a **Quick ratio** value of **0.81**, **SNY** is not doing good in the industry: **86.34%** of the companies in the same industry are doing better.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 1.21 | ||

Quick Ratio | 0.81 |

Measured over the past years, **SNY** shows a quite strong growth in **Earnings Per Share**. The EPS has been growing by **8.29%** on average per year.

EPS 1Y (TTM)17.29%

EPS 3Y11.26%

EPS 5Y8.29%

EPS growth Q2Q0.58%

Revenue 1Y (TTM)11.47%

Revenue growth 3Y6.45%

Revenue growth 5Y4.62%

Revenue growth Q2Q3.61%

The **Earnings Per Share** is expected to grow by **7.20%** on average over the next years.

The **Revenue** is expected to grow by **4.96%** on average over the next years.

EPS Next Y0.51%

EPS Next 2Y4.07%

EPS Next 3Y7.15%

EPS Next 5Y7.2%

Revenue Next Year0.9%

Revenue Next 2Y3.09%

Revenue Next 3Y4.36%

Revenue Next 5Y4.96%

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

With a **Price/Earnings** ratio of **10.03**, the valuation of **SNY** can be described as very reasonable.

Based on the **Price/Earnings** ratio, **SNY** is valued cheaply inside the industry as 88.78% of the companies are valued more expensively.

The average S&P500 **Price/Earnings** ratio is at **24.69**. **SNY** is valued rather cheaply when compared to this.

The **Price/Forward Earnings** ratio is **9.52**, which indicates a very decent valuation of **SNY**.

Compared to the rest of the industry, the **Price/Forward Earnings** ratio of **SNY** indicates a rather cheap valuation: **SNY** is cheaper than 87.80% of the companies listed in the same industry.

The average S&P500 **Price/Forward Earnings** ratio is at **19.79**. **SNY** is valued rather cheaply when compared to this.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 10.03 | ||

Fwd PE | 9.52 |

Based on the **Enterprise Value to EBITDA** ratio, **SNY** is valued cheaper than 95.12% of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 13.16 | ||

EV/EBITDA | 5.21 |

The high **PEG Ratio(NY)**, which compensates the Price/Earnings for growth, indicates **SNY** does not grow enough to justify the current Price/Earnings ratio.

PEG (NY)19.59

PEG (5Y)1.21

EPS Next 2Y4.07%

EPS Next 3Y7.15%

With a **Yearly Dividend Yield** of **4.13%**, **SNY** is a good candidate for dividend investing.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 4.13% |

The dividend of **SNY** has a limited annual growth rate of **2.52%**.

Dividend Growth(5Y)2.52%

Div Incr Years2

Div Non Decr Years2

DP35.1%

EPS Next 2Y4.07%

EPS Next 3Y7.15%

**SANOFI-ADR**

NASDAQ:SNY (11/30/2023, 4:35:24 PM)

After market: 46.75 0 (0%)**46.75**

**+0.15 (+0.32%) **

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)10-27 2023-10-27/bmo

Earnings (Next)N/A N/A

Inst Owners10.07%

Inst Owner Change-0.75%

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap117.24B

Analysts74

Price Target56.91 (21.73%)

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 4.13% |

Dividend Growth(5Y)2.52%

DP35.1%

Div Incr Years2

Div Non Decr Years2

Ex-Date05-30 2023-05-30 (1.9000852)

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)4.8%

Min EPS beat(2)3.28%

Max EPS beat(2)6.32%

EPS beat(4)3

Avg EPS beat(4)3.78%

Min EPS beat(4)-0.71%

Max EPS beat(4)6.32%

Revenue beat(2)2

Avg Revenue beat(2)56.73%

Min Revenue beat(2)4.58%

Max Revenue beat(2)108.87%

Revenue beat(4)4

Avg Revenue beat(4)59.61%

Min Revenue beat(4)4.58%

Max Revenue beat(4)117.19%

PT rev (1m)-6.54%

PT rev (3m)-5.75%

EPS NQ rev (1m)0.23%

EPS NQ rev (3m)-0.47%

EPS NY rev (1m)-0.02%

EPS NY rev (3m)-0.04%

Revenue NQ rev (1m)0.85%

Revenue NQ rev (3m)-2.45%

Revenue NY rev (1m)0%

Revenue NY rev (3m)-0.93%

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 10.03 | ||

Fwd PE | 9.52 | ||

P/S | 1.52 | ||

P/FCF | 13.16 | ||

P/OCF | 10.4 | ||

P/B | 1.47 | ||

P/tB | N/A | ||

EV/EBITDA | 5.21 |

EPS(TTM)4.66

EY9.97%

EPS(NY)4.91

Fwd EY10.5%

FCF(TTM)3.55

FCFY7.6%

OCF(TTM)4.5

OCFY9.62%

SpS30.72

BVpS31.81

TBVpS-0.53

PEG (NY)19.59

PEG (5Y)1.21

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 10.12% | ||

ROE | 17.47% | ||

ROCE | 19.35% | ||

ROIC | 15.53% | ||

ROICexc | 16.87% | ||

ROICexgc | 82.79% | ||

OM | 27.75% | ||

PM (TTM) | 18.09% | ||

GM | 70.31% | ||

FCFM | 11.56% |

ROA(3y)7.51%

ROA(5y)5.77%

ROE(3y)13.25%

ROE(5y)10.34%

ROIC(3y)6.95%

ROIC(5y)6.41%

ROICexc(3y)8.01%

ROICexc(5y)7.28%

ROICexgc(3y)38.1%

ROICexgc(5y)32.67%

ROCE(3y)8.66%

ROCE(5y)8%

ROICexcg growth 3Y21.31%

ROICexcg growth 5Y10.17%

ROICexc growth 3Y11.04%

ROICexc growth 5Y2.97%

OM growth 3Y7.11%

OM growth 5Y2.17%

PM growth 3Y36.08%

PM growth 5Y-4.51%

GM growth 3Y0.81%

GM growth 5Y0.55%

F-Score7

Asset Turnover0.56

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.22 | ||

Debt/FCF | 2.59 | ||

Debt/EBITDA | 0.71 | ||

Cap/Depr | 62.74% | ||

Cap/Sales | 3.08% | ||

Interest Coverage | 43.06 | ||

Cash Conversion | 44.82% | ||

Profit Quality | 63.9% | ||

Current Ratio | 1.21 | ||

Quick Ratio | 0.81 | ||

Altman-Z | 3.07 |

F-Score7

WACC6.96%

ROIC/WACC2.23

Cap/Depr(3y)60.69%

Cap/Depr(5y)50.45%

Cap/Sales(3y)5.21%

Cap/Sales(5y)5.19%

Profit Quality(3y)93.03%

Profit Quality(5y)115.45%

Growth

EPS 1Y (TTM)17.29%

EPS 3Y11.26%

EPS 5Y8.29%

EPS growth Q2Q0.58%

EPS Next Y0.51%

EPS Next 2Y4.07%

EPS Next 3Y7.15%

EPS Next 5Y7.2%

Revenue 1Y (TTM)11.47%

Revenue growth 3Y6.45%

Revenue growth 5Y4.62%

Revenue growth Q2Q3.61%

Revenue Next Year0.9%

Revenue Next 2Y3.09%

Revenue Next 3Y4.36%

Revenue Next 5Y4.96%

EBIT growth 1Y24.08%

EBIT growth 3Y14.02%

EBIT growth 5Y6.89%

EBIT Next Year18.05%

EBIT Next 3Y12.96%

EBIT Next 5Y8.95%

FCF growth 1Y39.13%

FCF growth 3Y11.98%

FCF growth 5Y8.95%

OCF growth 1Y24.88%

OCF growth 3Y10.91%

OCF growth 5Y7.36%